Physician profile
Ning Cao
NPI 1164476917
$12,527.24
in general payments reported to CMS, 2019-2025
29 companies · $2,353 in 2025
The $2,353 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $456 · 2021: $1,501 · 2022: $2,059 · 2023: $2,748 · 2024: $2,921 · 2025: $2,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,999 · Education: $23.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,998.81 |
| Education | $23.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,507.84 | 2021-2025 | Ubrelvy, Qulipta, Linzess |
| Astrazeneca Pharmaceuticals LP | $1,851.15 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,535.66 | 2019-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $933.32 | 2022-2025 | Ibsrela |
| Novo Nordisk INC | $916.85 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $835.29 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Pfizer INC. | $558.23 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $438.83 | 2020-2022 | |
| Amgen INC. | $396.51 | 2023-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $373.35 | 2019-2023 | Steglatro, Belsomra |
| Amarin Pharma, INC. | $333.14 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $267.83 | 2021-2025 | |
| Lilly USA, LLC | $256.23 | 2020-2025 | Mounjaro, Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $229.98 | 2022 | |
| Astellas Pharma US INC | $227.25 | 2019-2024 | Veozah, Myrbetriq |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $213.30 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $150.97 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.41 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $92.72 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $62.11 | 2021 | |
| Genentech USA, INC. | $61.78 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $48.25 | 2024 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $28.75 | 2025 | |
| Axsome Therapeutics, INC. | $21.68 | 2025 | Symbravo |
| Edwards Lifesciences Corporation | $21.19 | 2022 | |
| Esperion Therapeutics, INC. | $15.58 | 2020 | |
| Vistapharm, INC. | $14.64 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.37 | 2020 | |
| Allergan, INC. | $13.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ning Cao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.